IPO Issue Details
Issue Price / Price Band₹402 per share (Fixed Price)
Face Value₹1 Per Share
Lot Size35 Shares per Lot
Total Issue Size7,53,04,970 shares (aggregating up to ₹3,027.26 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenWed, 29 Jan 2025
Subscription CloseFri, 31 Jan 2025
Anchor AllotmentTue, 28 Jan 2025
Basis of AllotmentMon, 03 Feb 2025
Initiation of RefundsTue, 04 Feb 2025
Credit of Shares to DematTue, 04 Feb 2025
Listing DateTue, 04 Feb 2025
UPI Mandate Deadline2025-01-31
Application & Investment Details
Retail — Min (1 Lots)14,070 — 35 shares
Retail — Max (13 Lots)₹182,910 (13 Lots)
HNI — Min (72 Lots)10,13,040 — 2520 shares
EPS (Pre-IPO)₹3.08
EPS (Post-IPO)₹2.51
P/E Ratio (Pre-IPO)130.44x
P/E Ratio (Post-IPO)160.48x
Pre-IPO Promoter Holding30,84,17,160 shares
Post-IPO Promoter Holding31,58,79,846 shares
Fresh Issue Shares74,62,686 shares (aggregating up to ₹300.00 Cr)
Offer for Sale Shares6,78,42,284 shares of ₹1 (aggregating up to ₹2,727.26 Cr)
About Dr.Agarwal's Health Care Ltd.
Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.The Services provided by the company are:-Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.Competitive StrengthLargest eye care services provider in India with a trusted brandEnd-to-end, comprehensive eye care services offeringScalable, asset-light, hub-and-spoke operating modelProven clinical excellence is driven by a strong clinical board and a history of surgical innovations. Doctor-promoters leading a team of qualified medical professionals and supported by experienced managementProven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability
Objects of the Issue
Dr.Agarwal's Health Care Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Repayment/prepayment, in part or full, of certain of the borrowings
2
General corporate purposes and unidentified inorganic acquisition.
Shareholding & Lock-in
Pre-IPO Promoter Holding
30,84,17,160 shares
Post-IPO Promoter Holding
31,58,79,846 shares
Lock-in Period (30%)March 2, 2025
Lock-in Period (50%)May 1, 2025